FindTrial
Sign In

Randomized Control Trial of Levo-norgestrel Intrauterine System in Women Receiving Tamoxifen for Carcinoma of Breast

Randomized Control Trial of Levo-norgestrel Intrauterine System in Women Receiving Tamoxifen for Carcinoma of Breast

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000625
Enrollment
Unknown
Registered
2009-11-25
Start date
2001-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma of Breast on Tamoxifen

Interventions

Two Parallel groups:Surveillance (with transvaginal ultrasound scan and outpatient hysteroscopy) for control group against Surveillance (TVS and outpatient hysteroscopy) and intervention with mirena i

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Patients with breast cancer using tamoxifen as an adjuvant therapy 2. Patients willing to give written consent to participate the study

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1. Patients with previous history of endometrial hyperplasia or endometrial carcinoma 2. Patients who are contraindicated to the use of LNG-IUS 3. Patients who have no intact uterus 4. Patients refuse to participate the study

Design outcomes

Secondary

MeasureTime frame
Histology of endometrial pathology in both groups;Endometrial pathology by hysteroscopy in both groups;—

Countries

China

Contacts

Public ContactChan Shing Chee, Symphorosa
symphorosa@cuhk.edu.hk+852 2632 2583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 23, 2026